ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $38.66 million. The enterprise value is $41.19 million.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 25.27 million shares outstanding. The number of shares has increased by 75.08% in one year.
| Current Share Class | 25.27M |
| Shares Outstanding | 25.27M |
| Shares Change (YoY) | +75.08% |
| Shares Change (QoQ) | +2.89% |
| Owned by Insiders (%) | 18.86% |
| Owned by Institutions (%) | 3.26% |
| Float | 20.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.56 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12, with a Debt / Equity ratio of 0.21.
| Current Ratio | 0.12 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.14 |
Financial Efficiency
Return on equity (ROE) is -87.78% and return on invested capital (ROIC) is -38.03%.
| Return on Equity (ROE) | -87.78% |
| Return on Assets (ROA) | -29.01% |
| Return on Invested Capital (ROIC) | -38.03% |
| Return on Capital Employed (ROCE) | -56.00% |
| Weighted Average Cost of Capital (WACC) | 7.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$454,038 |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $24,154 in taxes.
| Income Tax | 24,154 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.83% in the last 52 weeks. The beta is 0.57, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -27.83% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 66.71 |
| Average Volume (20 Days) | 137,445 |
Short Selling Information
The latest short interest is 258,898, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 258,898 |
| Short Previous Month | 272,679 |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 2.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.03M |
| Pretax Income | -9.10M |
| Net Income | -8.63M |
| EBITDA | -8.01M |
| EBIT | -8.03M |
| Earnings Per Share (EPS) | -$0.38 |
Full Income StatementBalance Sheet
The company has $202,509 in cash and $2.73 million in debt, giving a net cash position of -$2.53 million or -$0.10 per share.
| Cash & Cash Equivalents | 202,509 |
| Total Debt | 2.73M |
| Net Cash | -2.53M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | 12.83M |
| Book Value Per Share | 0.43 |
| Working Capital | -4.74M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 24,092 |
| Net Borrowing | -291,074 |
| Free Cash Flow | -3.34M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |